S&P 500
7,226.20
+0.01%
Dow Jones
49,494.60
-0.62%
Nasdaq 100
27,685.40
+0.66%
Russell 2000
2,804.78
-0.02%
FTSE 100
10,364.50
0.00%
Nikkei 225
59,260.50
-0.78%

Health and Healthcare

MicroRx: Infectious Disease Supercluster

Photo of Douglas A. McIntyre
By Douglas A. McIntyre Published
Follow 24/7 Wall St. on Google
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

From BioHealth Investor

by Adam Rubenstein

Colorado State University announced MicroRx, an entity designed to ally academia and commercial enterprise to ultimately accelerate the bench-to-bedside process. Infectious Disease is the focus of this first CSU Supercluster which was borne out of CSU Ventures, lead by Mark Wdowik.

CSU is an international center of excellence for the study of infectious disease. The university was recently awarded a $40M grant from the National Institute of Allergy and Infectious Diseases, $17M from the NIH for the Regional Biocontainment Lab, and the CDC’s $80M research lab on the CSU Foothills Campus just to name a few of the headline poppers. University foci include mycobacterial diseases like tuberculosis, vector borne disease like West Nile fever and malaria, retroviral diseases like AIDS, and prion diseases like chronic wasting disease. Other CSU projects focus upon antimicrobial resistance, development of new approaches to control mosquitoes, ticks and other disease-carrying arthropods and food safety.

MicroRx is designed to now aid the movement of research discoveries to the market.

http://www.biohealthinvestor.com/

Photo of Douglas A. McIntyre
About the Author Douglas A. McIntyre →

Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.

McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.

His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.

A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.

TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.

McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.

Continue Reading

Visterra Gears Up for IPO
Chris Lange |

Visterra Gears Up for IPO

Visterra has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
3 Underfollowed Infectious Disease Stocks That Deserve More Attention
Trey Thoelcke |

3 Underfollowed Infectious Disease Stocks That Deserve More Attention

Infectious diseases always have been a hot topic in biotech, but over the past half decade more capital has been…
Top Baird Health Care and Biotech Picks Have Massive Upside Potential
Lee Jackson |

Top Baird Health Care and Biotech Picks Have Massive Upside Potential

One sector that has avoided much of the current trade and recession fear turmoil is health care, and especially the…
Jon C. Ogg |

GSK Takes Aim at AIDS/HIV Cure, Funding Company With University of North Carolina at Chapel Hill

ThinkstockAny time that you hear about new drugs and medical treatments, they tend to be around ongoing treatments rather than…
3 Recent Hot IPOs That Could Still Have Big Upside Potential
Lee Jackson |

3 Recent Hot IPOs That Could Still Have Big Upside Potential

We ran a screen of the Merrill Lynch research universe looking for IPOs that priced over the last year or…
Poverty Can Change Our Genes, Study Says
Hristina Byrnes |

Poverty Can Change Our Genes, Study Says

Researchers have discovered that poverty can affect our genetic makeup. According to a Northwestern University study just published in the…
Wall Street Hammered These 3 Biotech Stocks: Are They Really Screaming Buys?
Lee Jackson |

Wall Street Hammered These 3 Biotech Stocks: Are They Really Screaming Buys?

We combed through the Merrill Lynch database and found three biotech companies that at one time or another, when they…
FDA Accepts for Review the Newest Treatment for C Diff
Chris Lange |

FDA Accepts for Review the Newest Treatment for C Diff

Merck has just announced that the FDA has accepted a couple new drug applications for review, including for a treatment…
Jon C. Ogg |

As Antibiotics Stop Working, Five Biotechs Seek Cures

ThinkstockOne of the main concerns physicians have agreed upon in recent years has been the overuse of antibiotics by some…

Top Gaining Stocks

Cboe Global Markets
CBOE • Vol: 1,568,143
New Pluto Global
PSKY • Vol: 12,285,993
Seagate Technology
STX • Vol: 7,378,346
Oracle
ORCL • Vol: 26,317,675
Datadog
DDOG • Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ • Vol: 4,367,433
Clorox
CLX • Vol: 13,260,523
Stryker
SYK • Vol: 4,519,455
Mohawk Industries
MHK • Vol: 1,859,865
Amgen
AMGN • Vol: 3,818,618